GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » 12-1 Month Momentum %

Shield Therapeutics (LSE:STX) 12-1 Month Momentum % : -73.43% (As of May. 04, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-04), Shield Therapeutics's 12-1 Month Momentum % is -73.43%.

The industry rank for Shield Therapeutics's 12-1 Month Momentum % or its related term are showing as below:

LSE:STX's 12-1 Month Momentum % is ranked worse than
94.53% of 1116 companies
in the Drug Manufacturers industry
Industry Median: -6.64 vs LSE:STX: -73.43

Competitive Comparison of Shield Therapeutics's 12-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shield Therapeutics's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's 12-1 Month Momentum % falls into.



Shield Therapeutics  (LSE:STX) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shield Therapeutics  (LSE:STX) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Shield Therapeutics 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shield Therapeutics (LSE:STX) Business Description

Traded in Other Exchanges
Address
Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.